Investigational drug · Phase 2
BC3195
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Locally Advanced or Metastatic Solid Tumors.
Phase 2Last checked: Nov 19, 2026Latest source record: May 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "BC3195"
First trial start
2026
Mar 31, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BC3195", any sponsor or status.
Conditions studied
As listed on its trial records.
- Locally Advanced or Metastatic Solid Tumors
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "BC3195" as an intervention, largest first.
Biocity Biopharmaceutics Co., Ltd.Industry
NCT06548672 · 148 participants (planned) · Start Jun 24, 2024 · Primary completion Apr 30, 2027
Drug: BC3195 · For: Advanced Cancer; Metastatic Solid Tumor
Sites: Cleveland, Ohio
Biocity Biopharmaceutics Co., Ltd.Industry
NCT07469774 · 111 participants (planned) · Start Mar 31, 2026 · Primary completion Dec 31, 2027
Drug: BC3195; Pembrolizumab/KEYTRUDA® · For: Locally Advanced or Metastatic Solid Tumors
Sites: Guangzhou, China
Biocity Biopharmaceutics Co., Ltd.Industry
NCT05957471 · 27 participants (planned) · Start Jun 26, 2023 · Primary completion Jun 2025
Drug: Drug: BC3195 for Injection · For: Locally Advanced or Metastatic Solid Tumors
Sites: Guangzhou, China
Newest research
PubMed records naming it or its code names, newest first.
- First case report of transformation of adenocarcinoma to adenosquamous carcinoma with giant-cell carcinoma harboring HER2 mutation after zongertinib (BI 1810631) resistance.
Lin JX, Yin K, Yan LX, et al. · Lung Cancer 2026
Also in development for Locally Advanced or Metastatic Solid Tumors
- CVL237Phase 22 trials
Convalife (Shanghai) Co., Ltd. · Advanced Solid Tumors, Locally Advanced or Metastatic Solid Tumors, PTEN Loss or Low Expression
- YL202 should be intravenously infusedPhase 22 trials
MediLink Therapeutics (Suzhou) Co., Ltd. · NSCLC, Breast Cancer, HNSCC
- AP203Phase 21 trial
AP Biosciences Inc. · Locally Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC)
- ASP388BPhase 21 trial
Astellas · Locally Advanced or Metastatic Solid Tumors
- DA-4505Phase 21 trial
Dong-A ST Co., Ltd. · Locally Advanced or Metastatic Solid Tumors
- PTT-936Phase 21 trial
Pyrotech Therapeutics, Inc. · Locally Advanced or Metastatic Solid Tumors
- XZP-5955Phase 21 trial
Xuanzhu Biopharmaceutical Co., Ltd. · Locally Advanced or Metastatic Solid Tumors, Locally Advanced or Metastatic Non-small Cell Lung Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.